Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians.

ABSTRACT: Immunotherapy using immune checkpoint inhibitors (ICIs) is a breakthrough in oncology development and has been applied to multiple solid tumors. However, unlike traditional cancer treatment approaches, immune checkpoint inhibitors (ICIs) initiate indirect cytotoxicity by generating inflammation, which causes enlargement of the lesion in some cases. Therefore, rather than declaring progressive disease (PD) immediately, confirmation upon follow-up radiological evaluation after four-eight weeks is suggested according to immune-related Response Evaluation Criteria in Solid Tumors (ir-RECIST). Given the difficulty for clinicians to immediately distinguish pseudoprogression from true disease progression, we need novel tools to assist in this field. Radiomics, an innovative data analysis techniqu

SUBMITTER: Zhou H 

PROVIDER: S-EPMC10014595 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature